Jeffrey N. Simmons Sells 9,625 Shares of Eli Lilly and Co (NYSE:LLY) Stock

Eli Lilly and Co (NYSE:LLY) SVP Jeffrey N. Simmons sold 9,625 shares of Eli Lilly and stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $81.12, for a total value of $780,780.00. Following the sale, the senior vice president now directly owns 152,120 shares in the company, valued at $12,339,974.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Shares of Eli Lilly and Co (NYSE LLY) opened at $76.25 on Tuesday. The firm has a market cap of $83,960.00, a P/E ratio of -381.25, a price-to-earnings-growth ratio of 1.39 and a beta of 0.23. Eli Lilly and Co has a one year low of $73.69 and a one year high of $89.09. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.06. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 31.44%. The company had revenue of $6.16 billion during the quarter, compared to the consensus estimate of $5.93 billion. During the same period last year, the firm earned $0.95 earnings per share. Eli Lilly and’s revenue was up 7.0% compared to the same quarter last year. equities research analysts anticipate that Eli Lilly and Co will post 4.88 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be paid a dividend of $0.5625 per share. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 annualized dividend and a dividend yield of 2.95%. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and’s payout ratio is presently -1,040.00%.

Several institutional investors have recently modified their holdings of LLY. Gradient Investments LLC purchased a new position in Eli Lilly and in the fourth quarter valued at $103,000. Acrospire Investment Management LLC increased its holdings in Eli Lilly and by 16.7% in the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after buying an additional 200 shares in the last quarter. MPS Loria Financial Planners LLC purchased a new position in Eli Lilly and in the second quarter valued at $128,000. San Francisco Sentry Investment Group CA purchased a new position in Eli Lilly and in the second quarter valued at $129,000. Finally, Front Row Advisors LLC purchased a new position in Eli Lilly and in the fourth quarter valued at $137,000. 76.20% of the stock is owned by hedge funds and other institutional investors.

LLY has been the topic of a number of analyst reports. BMO Capital Markets set a $73.00 price target on Eli Lilly and and gave the stock a “sell” rating in a research report on Monday, October 16th. Leerink Swann boosted their target price on shares of Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 target price for the company in a research note on Thursday, October 26th. Berenberg Bank restated a “buy” rating and issued a $98.00 price objective on shares of Eli Lilly and in a research note on Thursday, October 26th. Finally, Morgan Stanley upped their price objective on Eli Lilly and from $86.00 to $90.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 21st. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $92.02.

TRADEMARK VIOLATION WARNING: This piece was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Insider Buying and Selling by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with's FREE daily email newsletter.

Leave a Reply